Veru (VERU) Registration filing summary

Company overview and business model

• Focuses on developing novel medicines for cardiometabolic and inflammatory diseases, with two late-stage drug candidates: enobosarm (for improved body composition in obesity) and sabizabulin (for chronic inflammation in atherosclerotic cardiovascular disease).

• Incorporated in Wisconsin in 1971, with principal offices in Miami, Florida.

Financial performance and metrics

• Net tangible book value as of December 31, 2025, was approximately $29.4 million, or $1.83 per share.

• After the offering, net tangible book value would be $79.7 million, or $2.00 per share, with immediate dilution of $1.00 per share to new investors exercising warrants at $3.00 per share.

• 16,050,320 shares of common stock outstanding as of March 31, 2026.

Use of proceeds and capital allocation

• Net proceeds intended for general corporate purposes, including working capital, R&D, clinical trials, marketing, drug development, acquisitions, operating expenses, and legal proceedings.

• Management has broad discretion over timing and application of proceeds; funds may be invested in short- and medium-term, interest-bearing obligations pending use.